| Literature DB >> 22998334 |
M Johnson1, R Jones, C Freeman, H B Woods, M Gillett, E Goyder, N Payne.
Abstract
OBJECTIVE: Randomized trials provide evidence that intensive lifestyle interventions leading to dietary and physical activity change can delay or prevent Type 2 diabetes. Translational studies have assessed the impact of interventions based on, but less intensive than, trial protocols delivered in community settings with high-risk populations. The aim of this review was to synthesize evidence from translational studies of any design to assess the impact of interventions delivered outside large randomized trials.Entities:
Mesh:
Year: 2013 PMID: 22998334 PMCID: PMC3555428 DOI: 10.1111/dme.12018
Source DB: PubMed Journal: Diabet Med ISSN: 0742-3071 Impact factor: 4.359
FIGURE 1Flow chart of paper selection
Characteristics of intervention studies based on the Diabetes Prevention Program (DPP) and the Diabetes Prevention Study (DPS)
| Author, country, setting | Study design | Population | Intervention | Comparator(s) | Length of follow-up |
|---|---|---|---|---|---|
| Diabetes Prevention Program (DPP) [ | Randomized controlled trial. Three groups | Adults with fasting plasma glucose 5.3–6.9 mmol/l; impaired glucose tolerance; BMI ≥ 24 kg/m2 (22 in South Asian population) | 16 core sessions 30–60 min. Maintenance: phone or in person 1–2 times monthly | Standard 20- to 30-min session and written materials | 3.2 years and 10 years |
| Ackermann | Pilot cluster—randomized trial (DEPLOY). Two groups | Semi-urban. American Diabetes Association risk score ≥ 10, BMI ≥ 24 kg/m2 | 16 group sessions ( | Brief counselling alone | 12 months |
| Almeida | Non-randomized, longitudinal. Two groups (matched pairs) | Newly diagnosed pre-diabetes. Impaired glucose tolerance (100–125 mg/dl) | Two 4- to 6-monthly group sessions ( | Usual care | 12 months |
| Amundsen | Evaluation. One group | BMI ≥ 25 kg/m2 One or more: impaired fasting glucose/impaired glucose tolerance; hypertension; hyperlipidaemia; history of gestational diabetes; birth to baby of > 4 kg | 16 group sessions ( | N/A | 12 months |
| Boltri | Pilot pre-test post-test. One group | Pre-diabetes (fasting glucose 100–125 mg/dl) | 16 sessions over 4 months. Modified for church implementation. Culturally sensitive | N/A | 12 months |
| Davis-Smith | Evaluation One group | Church congregation. American Diabetes Association risk score ≥ 10. Fasting blood glucose 100–125 mg/dl | Six sessions over 7 weeks | N/A | 12 months |
| Faridi | Evaluation. Two groups | African American church congregations. One or more: BMI > 25 kg/m2; parent/sibling with diabetes; history of gestational diabetes | Number of sessions not standardized. Flexible content and mode of delivery (either group or individual) | Intervention compared in two geographical settings | 12 months |
| Katula | Randomized controlled trial (HELP-PD). Two groups | BMI between 25–40 kg/m2 Pre-diabetes identified on two occasions (HOMA-IR). | 24 group sessions (weekly for 6 months). Maintenance: monthly sessions for 18 months | Two individual sessions with nutritionist over 3 months | 24 months |
| Kramer | Non-randomized prospective. One-group | 25–74 years BMI ≥ 25 kg/m2 Fasting glucose 100–125 mg/dl | 12 group sessions of 1-h duration delivered over 12–15 weeks | N/A | 12 months |
| Kulzer | Randomized controlled trial (PREDIAS). Two groups | Age 20–70 years, BMI ≥ 26 kg/m2, impaired glucose tolerance or impaired fasting glucose. Diabetes Risk Score > 10 | 12 group sessions of ∼90 min. Eight core sessions over 8 weeks then every 2 weeks | Written information and materials | 12 months |
| McTigue | Controlled cohort Study (WiLLoW). Two groups | BMI ≥ 25 kg/m2 | 12 group sessions. Maintenance: monthly sessions for 8 months | Individuals that did not enrol on the programme | 12 months |
| McTigue | Cohort study. One group | Age 18–80 years. Access to Internet. BMI ≥ 25 kg/m2 History of cardiovascular disease risk factors (including pre-diabetes) | 16 weekly 30- to 45-min online sessions. Maintenance: 8-monthly lessons | N/A | 12 months |
| Seidal | Non-randomized prospective. One-group | BMI ≥ 25 kg/m2 ≥ 3 components of the metabolic syndrome | 12 group sessions ( | N/A | 6 months |
| Vadheim | Non-randomized controlled trial. Two groups | Age > 21 years BMI ≥ 25 kg/m2 At least one diabetes/cardiovascular disease risk factor or history of gestational diabetes Birth to baby of > 4 kg | 16 weekly tele-health sessions, 60 min in duration. Maintenance: 6 × monthly sessions | Hospital site: 2- to 4-weekly supervised physical activity sessions | 16 weeks |
| Whittemore | Pilot randomized controlled trial Two groups | Age ≥ 21 years BMI ≥ 25 kg/m2 If < 65 years: Family history of Type 2 diabetes History of gestational diabetes Birth to baby of > 4 kg Ethnic group at high risk | Six in-person 20-min sessions and five phone sessions over 6 months | One nurse practitioner and one nutrition session | 6 months |
| Diabetes Prevention Study (DPS) [ | Randomized controlled trial. Two groups | Impaired glucose tolerance and BMI ≥ 25 kg/m2
| Seven sessions with nutritionist during first 12 months, followed by visits every 3 months | General information at start of trial | 3 years |
| Absetz | Pre-test post-test (GOAL). One group. | Diabetes risk score ≥ 10 | Six group counselling sessions ( | N/A | 1 and 3 years |
| Laatikainen | Pre-test post-test Greater Green Triangle). Two groups | Diabetes risk score ≥ 12 | Six group sessions over 8 months; 90-min duration. Five sessions in first 3 months; final session at 8 months | N/A | 12 months |
| Saaristo | Pre-test post-test (FIN-D2D). One group | FINDRISC ≥ 15 | Four to 9 group weekly or biweekly sessions and some individual sessions. Follow-up session 1 month after intervention | N/A | 12 months |
FINDRISC, Finnish Diabetes Risk Score; HELP-PD, Healthy Living Partnerships to Prevent Diabetes; HOMA-IR, homeostasis model assessment of insulin resistance; N/A, not available; PREDIAS, Prevention of diabetes self-management program; WiLLoW, Weight Loss through Living Well.
Findings from intervention studies based on the Diabetes Prevention Program (DPP) and Diabetes Prevention Survey (DPS)
| Author, country, setting, follow-up | Sample | Changes in mean blood glucose at follow-up | Mean weight loss at follow-up | Change in mean waist circumference at follow-up | Lost to follow-up |
|---|---|---|---|---|---|
| Diabetes Prevention Program (DPP) [ | Lifestyle intervention | Intervention: HbA1c 41 mmol/mol (5.9%) to 40 mmol/mol (5.8%) Control: HbA1c 41 mmol/mol (5.9%) to 42 mmol/mol (6.0%) at 12 months | 7 kg over 12 months, then a gradual regain to 2 kg at 10 years | Not reported | Not seen in 18 months: 65 (11%) in lifestyle intervention arm 69 (11.9%) in control arm |
| Ackermann | Intervention: HbA1c (−0.1%)Control: no change ( | Intervention: 6.0 kg Control: 1.8 kg ( | Not reported | 15% intervention 17% control | |
| Almeida | Not reported | Intervention: 1.4 kg (95% CI 1.6 kg to 1.1 kg) Control: 0.6 kg [95% CI 0.9 kg (2.0 lbs) to 0.4 kg (0.8 lbs)] ( | Not reported | 60 from each arm (total 15.8%) at 12 months | |
| Amundsen | Not reported Fasting blood glucose: −0.26 mmol/l ( | 6.7 kg ( | Not reported Not reported | 17.5% at 4 months | |
| Boltri | −0.22 mmol/l | 0.45 kg at 12 months (2.52 kg at 6 months) | Not reported | None reported | |
| Davis-Smith | Fasting serum glucose −0.5 mmol/l | 4.0, 3.0 and 4.8 kg immediately after the intervention, and at 6- and 12-month follow-up, respectively. No other details reported | Not reported | ||
| Faridi | 13 congregations Intervention: | Not reported | Intervention: +0.32 lbs (0.15 kg) ( | Not reported | Intervention: |
| Katula | −0.21 mmol/l ( | −2.57 kg ( | −5.05 cm ( | Attrition at 6 months: Intervention: 1% Control: 2% Attrition at 12 months: Intervention: 1% Control: 2% | |
| Kramer | −0.08 mmol/l or −1.4% ( | Phase 2: −4.5 kg ( | Phase 2: −4.3 cm (−1.7 inches) (−4.2%), ( | Phase 1: 18 (35%) did not attend post-assessment visit Phase 2: 2 (4.8%) did not attend post-assessment visit; 12 (28.6%) did not attend 12-month visit | |
| Kulzer | Fasting blood glucose −4.3 mg/dl (0.24 mmol/l) ( | −3.8 kg ( | −4.1 cm ( | 17 lost to follow-up (9%) | |
| McTigue | Not reported | Intervention: 5.19 kg (95% CI −7.71 to −2.68) Control: +0.21 kg (95% CI −1.50 to 1.93) ( | Not reported | Follow-up data unavailable for 7% of sample [attrition | |
| McTigue | Not reported | 4.79 kg (95% CI −7.36 to −2.22) | Not reported | Attrition: | |
| Seidal | Proportion with ≥ 5.5 mmol/l increased over time (baseline 42%; 3 months 51%; 6 months 61%; | 46% lost ≥ 5% body weight; 26% lost ≥ 7% after 3 months. At 6 months this was sustained by 87 and 67%, respectively | Abdominal obesity decreased: Baseline 90%; 3 months 82%; 6 months 68% ( | 10.4% attrition at 3 months; 35% at 6 months | |
| Vadheim | Not reported | Intervention: 6.7 kg ( | Not reported | On site: 0% Tele-health: 12.5% at 16 weeks | |
| Whittemore | Intervention: trend in oral glucose tolerance test 0.01 mmol/l per month Control: 0.83 mmol/l per month | Intervention: 1.5% ( | Not reported | 12% attrition at 6 months | |
| Diabetes Prevention Survey (DPS) [ | Fasting plasma glucose. Intervention: −0.2 mmol/l ( | Intervention: −4.2 kg( | Intervention: −4.4 cm ( | 59% attrition at 12 months | |
| Absetz | Fasting plasma glucose: +0.1 mmol/l ( | −0.8 kg ( | −1.6 cm ( | 23% attrition at 3 years | |
| Laatikainen | Fasting plasma glucose: −0.14 mmol/l (95% CI −0.20 to −0.07) (−2.5%) Oral glucose tolerance test: −0.58 (95% CI −0.79 to −0.36) (−8.6%) | −2.36 (95% CI −3.19 to −1.85) | −4.17 cm (95% CI −4.87 to −3.48) (−4.0%) Some reduction in 75% of sample | 74 (23.8%) non-completers | |
| Saaristo | Not reported | Males: −1.2 kg ( | Males: −1.3 cm ( | 32% attrition |
NS, not signifcant;